new
   Indications of Etrasimod
502
Sep 28, 2025

Etrasimod is a novel sphingosine-1-phosphate receptor modulator, first approved for marketing by the U.S. Food and Drug Administration (FDA) in 2023. As an oral medication for the treatment of moderately to severely active ulcerative colitis, etrasimod provides a new therapeutic option for patients with this chronic inflammatory bowel disease.

Indications of Etrasimod

Main Therapeutic Area

Clinical studies have confirmed that etrasimod is specifically indicated for the treatment of moderately to severely active ulcerative colitis in adults.

Ulcerative colitis is a chronic, non-specific inflammatory bowel disease that primarily affects the colonic mucosa and submucosa. Its clinical manifestations include symptoms such as diarrhea, mucopurulent bloody stools, and abdominal pain.

Etrasimod exerts its effects by regulating the immune system, which can effectively control disease activity and improve patients’ symptoms.

Characteristics of Eligible Populations

This medication is indicated for adult patient populations and has demonstrated efficacy in patients with moderate to severe active disease in clinical trials.

It is important to note that etrasimod is not indicated for patients with mild ulcerative colitis, nor is it suitable for pediatric patient populations.

Specifications and Characteristics of Etrasimod

Dosage Form and Specifications

The currently marketed dosage form of etrasimod is oral film-coated tablets, with each tablet containing 2mg of etrasimod as the active ingredient.

This specification is the recommended therapeutic dose determined based on clinical trial results, which balances therapeutic efficacy and safety.

Description of Physical Characteristics

Appearance and Form: Round tablets.

Color Characteristic: Green film coating.

Imprint Information: One side is embossed with the letters "ETR", and the other side is embossed with the number "2", facilitating identification and dose differentiation.

Storage Methods of Etrasimod

Routine Storage Conditions

Temperature Control: Should be stored at room temperature between 20°C and 25°C.

Humidity Management: Maintain a dry environment and protect from moisture.

Light Protection: Store away from light, preferably keeping the medication in its original packaging until use.

Special Precautions

The medication should be kept out of the reach of children.

Do not store the medication in high-humidity areas such as bathrooms or kitchens.

Regularly inspect the appearance of the medication; if abnormal discoloration or changes in characteristics are found, discontinue use.

Pay attention to the expiration date of the medication; expired medications should be disposed of promptly.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
Indications for Odevixibat (Bylvay)

Odevixibat (Bylvay) is an ileal bile acid transporter (IBAT) inhibitor, mainly indicated for the treatment of...

Friday, October 24th, 2025, 13:40
How to Use Pramipexole

Pramipexole is a non-ergot dopamine receptor agonist, mainly used for the treatment of Parkinson's disease (PD)...

Friday, October 24th, 2025, 13:37
Indications of Pomalidomide

Pomalidomide is a thalidomide analog developed by Bristol-Myers Squibb.

Indications of...

Friday, October 24th, 2025, 13:34
How to Purchase Pramipexole

Pramipexole is a non-ergot dopamine receptor agonist, primarily indicated for the treatment of Parkinson's...

Friday, October 24th, 2025, 13:31
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved